Europe Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023

List of Tables

The Europe Oncology Drugs Market would witness market growth of 7.5% CAGR during the forecast period (2023-2030).

Early cancer detection improves the prognosis for survival, reduces morbidity, and facilitates cost-effective treatment by increasing the likelihood of therapy response. An increase in the incidence of various cancer conditions and the prevalence of cancer disease, a rise in the popularity of advanced therapies (biologic and targeted drug therapies), and a geriatric population surge all contribute to the expansion of the market. On the contrary, abundant prospects for promising pharmaceuticals in the pipeline and the considerable potential of emerging economies are anticipated to generate profitable opportunities throughout the projected timeframe.

The field of oncology has undergone a revolutionary transformation over the past few decades, with groundbreaking advancements in cancer research, diagnosis, and treatment. The dynamic market for these drugs is central to this evolution, pivotal in addressing the complex challenges of various cancer types. As the understanding of the molecular and genetic underpinnings of cancer deepens, pharmaceutical companies are racing to develop innovative therapies that target specific pathways and mechanisms, ushering in a new era of precision medicine.

Europe actively participates in international clinical trials, contributing to the testing and development of novel oncology drugs. Collaborative efforts between European countries and global research networks facilitate the recruitment of diverse patient populations for clinical studies. Liver cancer has seen a notable increase in incidence rates in the UK. This rise is associated with various risk factors, such as chronic hepatitis B and C diseases, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and other liver conditions. The high incidence rates drive the demand for effective oncology drugs. The aforementioned factors will drive the market growth in this region.

The Germany region dominated the Europe Oncology Drugs Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $18,719.9 million by 2030. The UK region is exhibiting a CAGR of 6.6% during (2023 - 2030). Additionally, The France region would experience a CAGR of 8.3% during (2023 - 2030).

Based on Indication, the market is segmented into Breast Cancer, Prostate Cancer, Lung Cancer, Stomach Cancer, Colorectal Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer and Other Cancer. Based on Drug Class Type, the market is segmented into Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc. and Pfizer Inc.

Scope of the Study

Market Segments covered in the Report:

By Indication

Breast Cancer
Prostate Cancer
Lung Cancer
Stomach Cancer
Colorectal Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancer

By Drug Class Type

Targeted Therapy
Immunotherapy (Biologic Therapy)
Chemotherapy
Hormonal Therapy

By Country

Germany
UK
France
Russia
Spain
Italy
Rest of Europe

Companies Profiled

AbbVie, Inc.
Amgen, Inc.
Astellas Pharma, Inc.
AstraZeneca PLC
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Novartis AG
Merck & Co., Inc.
Pfizer Inc.

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Europe Oncology Drugs Market, by Indication
- 1.4.2 Europe Oncology Drugs Market, by Drug Class Type
- 1.4.3 Europe Oncology Drugs Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global

4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
- 4.2.1 Partnerships, Collaborations and Agreements
- 4.2.2 Product Launches and Product Expansions
- 4.2.3 Acquisition and Mergers
4.3 Top Winning Strategies
- 4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
- 4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2019, Mar - 2023, Nov) Leading Players
4.4 Porter's Five Forces Analysis

Chapter 5. Europe Oncology Drugs Market by Indication

5.1 Europe Breast Cancer Market by Country
5.2 Europe Prostate Cancer Market by Country
5.3 Europe Lung Cancer Market by Country
5.4 Europe Stomach Cancer Market by Country
5.5 Europe Colorectal Cancer Market by Country
5.6 Europe Liver Cancer Market by Country
5.7 Europe Esophagus Cancer Market by Country
5.8 Europe Cervical Cancer Market by Country
5.9 Europe Kidney Cancer Market by Country
5.10. Europe Bladder Cancer Market by Country
5.11 Europe Other Cancer Market by Country

Chapter 6. Europe Oncology Drugs Market by Drug Class Type

6.1 Europe Targeted Therapy Market by Country
6.2 Europe Immunotherapy (Biologic Therapy) Market by Country
6.3 Europe Chemotherapy Market by Country
6.4 Europe Hormonal Therapy Market by Country

Chapter 7. Europe Oncology Drugs Market by Country

7.1 Germany Oncology Drugs Market
- 7.1.1 Germany Oncology Drugs Market by Indication
- 7.1.2 Germany Oncology Drugs Market by Drug Class Type
7.2 UK Oncology Drugs Market
- 7.2.1 UK Oncology Drugs Market by Indication
- 7.2.2 UK Oncology Drugs Market by Drug Class Type
7.3 France Oncology Drugs Market
- 7.3.1 France Oncology Drugs Market by Indication
- 7.3.2 France Oncology Drugs Market by Drug Class Type
7.4 Russia Oncology Drugs Market
- 7.4.1 Russia Oncology Drugs Market by Indication
- 7.4.2 Russia Oncology Drugs Market by Drug Class Type
7.5 Spain Oncology Drugs Market
- 7.5.1 Spain Oncology Drugs Market by Indication
- 7.5.2 Spain Oncology Drugs Market by Drug Class Type
7.6 Italy Oncology Drugs Market
- 7.6.1 Italy Oncology Drugs Market by Indication
- 7.6.2 Italy Oncology Drugs Market by Drug Class Type
7.7 Rest of Europe Oncology Drugs Market
- 7.7.1 Rest of Europe Oncology Drugs Market by Indication
- 7.7.2 Rest of Europe Oncology Drugs Market by Drug Class Type

Chapter 8. Company Profiles

8.1 AbbVie, Inc.
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Regional Analysis
- 8.1.4 Research & Development Expense
- 8.1.5 Recent strategies and developments:
  - 8.1.5.1 Partnerships, Collaborations, and Agreements:
  - 8.1.5.2 Acquisition and Mergers:
- 8.1.6 SWOT Analysis
8.2 Amgen, Inc.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expenses
- 8.2.5 Recent strategies and developments:
  - 8.2.5.1 Acquisition and Mergers:
- 8.2.6 SWOT Analysis
8.3 Astellas Pharma, Inc.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
  - 8.3.5.1 Partnerships, Collaborations, and Agreements:
  - 8.3.5.2 Acquisition and Mergers:
- 8.3.6 SWOT Analysis
8.4 AstraZeneca PLC
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expenses
- 8.4.5 Recent strategies and developments:
  - 8.4.5.1 Partnerships, Collaborations, and Agreements:
  - 8.4.5.2 Product Launches and Product Expansions:
- 8.4.6 SWOT Analysis
8.5 Bristol Myers Squibb Company
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
  - 8.5.5.1 Partnerships, Collaborations, and Agreements:
  - 8.5.5.2 Product Launches and Product Expansions:
  - 8.5.5.3 Acquisition and Mergers:
- 8.5.6 SWOT Analysis
8.6 F. Hoffmann-La Roche Ltd.
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental and Regional Analysis
- 8.6.4 Research & Development Expense
- 8.6.5 Recent strategies and developments:
  - 8.6.5.1 Partnerships, Collaborations, and Agreements:
  - 8.6.5.2 Product Launches and Product Expansions:
  - 8.6.5.3 Acquisition and Mergers:
- 8.6.6 SWOT Analysis
8.7 Johnson & Johnson
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Segmental & Regional Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 Recent strategies and developments:
  - 8.7.5.1 Partnerships, Collaborations, and Agreements:
  - 8.7.5.2 Acquisition and Mergers:
- 8.7.6 SWOT Analysis
8.8 Novartis AG
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
  - 8.8.5.1 Partnerships, Collaborations, and Agreements:
- 8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expenses
- 8.9.5 Recent strategies and developments:
  - 8.9.5.1 Partnerships, Collaborations, and Agreements:
  - 8.9.5.2 Acquisition and Mergers:
- 8.9.6 SWOT Analysis
8.10. Pfizer, Inc.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Regional & Segmental Analysis
- 8.10.4 Research & Development Expense
- 8.10.5 Recent strategies and developments:
  - 8.10.5.1 Partnerships, Collaborations, and Agreements:
- 8.10.6 SWOT Analysis

LIST OF TABLES

TABLE 1 Europe Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 2 Europe Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements- Oncology Drugs Market
TABLE 4 Product Launches And Product Expansions- Oncology Drugs Market
TABLE 5 Acquisition and Mergers- Oncology Drugs Market
TABLE 6 Europe Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 7 Europe Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 8 Europe Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 9 Europe Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 10 Europe Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 11 Europe Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 12 Europe Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 13 Europe Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 14 Europe Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 15 Europe Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 16 Europe Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 17 Europe Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 18 Europe Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 19 Europe Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 20 Europe Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 21 Europe Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 22 Europe Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 23 Europe Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 24 Europe Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 25 Europe Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 26 Europe Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 27 Europe Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 28 Europe Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 29 Europe Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 30 Europe Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 31 Europe Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 32 Europe Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 33 Europe Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 34 Europe Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 35 Europe Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 36 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 37 Europe Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 38 Europe Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 39 Europe Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 40 Europe Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 41 Europe Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 42 Germany Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 43 Germany Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 44 Germany Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 45 Germany Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 46 Germany Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 47 Germany Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 48 UK Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 49 UK Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 50 UK Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 51 UK Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 52 UK Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 53 UK Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 54 France Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 55 France Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 56 France Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 57 France Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 58 France Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 59 France Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 60 Russia Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 61 Russia Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 62 Russia Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 63 Russia Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 64 Russia Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 65 Russia Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 66 Spain Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 67 Spain Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 68 Spain Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 69 Spain Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 70 Spain Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 71 Spain Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 72 Italy Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 73 Italy Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 74 Italy Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 75 Italy Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 76 Italy Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 77 Italy Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 78 Rest of Europe Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 79 Rest of Europe Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 80 Rest of Europe Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 81 Rest of Europe Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 82 Rest of Europe Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 83 Rest of Europe Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 84 Key information - AbbVie, Inc.
TABLE 85 Key Information - Amgen, Inc.
TABLE 86 key information - Astellas Pharma, Inc.
TABLE 87 KEY INFORMATION - AstraZeneca PLC
TABLE 88 Key Information - Bristol Myers Squibb Company
TABLE 89 Key Information - F. Hoffmann-La Roche Ltd.
TABLE 90 Key Information - Johnson & Johnson
TABLE 91 Key Information - Novartis AG
TABLE 92 Key Information - Merck & Co., Inc.
TABLE 93 Key Information - Pfizer, Inc.

Europe Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030

Description

Table of Contents